Case report: Uridine triacetate in the management of delayed onset 5-fluorouracil toxicity: A case report and review of literature
Authors:
Open Access
- 7 September 2022
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 977734
Abstract
5-fluorouracil (5FU) and capecitabine are fluoropyrimidine anti-neoplastic drugs commonly used in the treatment of different types of cancer. Hereditary dihydropyrimdine deaminase (DPD), thymidylate synthase mutations and drug overdose may lead to life-threatening toxicities. Uridine triacetate (UTA) is an emergency treatment for overdoses and early onset, severe or life-threatening toxicities from fluoropyrimidines. It is approved for use in adults and children within 96 h of last fluoropyrimidine administration. We present the case of a 64-year-old male treated with 5-FU and oxaliplatin as adjuvant systemic therapy for stage IIIA rectal cancer who developed delayed central nervous system toxicity 18 days after initiating chemotherapy. He had rapidly worsening encephalopathy and ataxia. Laboratory workups, MRI brain and EEG were negative. He was started on UTA with concerns of 5-FU toxicity due to the life-threatening nature of his condition even beyond the recommended 96-h time cut-off. He had rapid improvement in clinical status and resolution of encephalopathy. DPD deficiency testing later resulted as heterozygous for IVS14+1G>A allele indicating enzyme deficiency. This report demonstrates the importance of identifying delayed side effects with fluoropyrimidine therapy and potential treatment for reversing these effects. We also did an extensive literature review and obtained reports from the uridine triacetate clinical trials on patients receiving UTA after the 96-h cut-off. Based on our experience and previous published reports, a patient developing life-threatening delayed 5-FU toxicity should also be considered for UTA on a case-by-case basis.Keywords
This publication has 21 references indexed in Scilit:
- Irreversible cerebellar toxicity after infusional 5-flurouracil therapyIndian Journal of Cancer, 2015
- Fatal outcome of posterior “reversible” encephalopathy syndrome in metastatic colorectal carcinoma after irinotecan and fluoropyrimidine chemotherapy regimenWorld Journal of Surgical Oncology, 2014
- Local Treatment of Hand-Foot Syndrome with Uridine/Thymidine:In VitroAppraisal on a Human Keratinocyte Cell Line HaCaTThe Scientific World Journal, 2012
- Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous systemJournal of Biology, 2008
- 5-Fluorouracil dose escalation enabled with PN401 (triacetyluridine): toxicity reduction and increased antitumor activity in miceCancer Chemotherapy and Pharmacology, 2005
- 5-Fluorouracil-induced leukoencephalopathy in patients with breast cancerJournal of Korean Medical Science, 2001
- Phase I and Pharmacologic Study of PN401 and Fluorouracil in Patients With Advanced Solid MalignanciesJournal of Clinical Oncology, 2000
- Prolonged Severe 5-Fluorouracil-Associated Neurotoxicity in a Patient with Dihydropyrimidine Dehydrogenase DeficiencyCancer Investigation, 1999
- Cerebral Demyelination with 5-Fluorouracil and LevamisoleCancer Investigation, 1994
- Multifocal inflammatory leukoencephalopathy with 5‐fluorouracil and levamisoleAnnals of Neurology, 1992